top of page

News

 

 

September 1, 2022

​

Adecto Pharmaceuticals awarded Phase II NCI SBIR grant to continue development of an ADAM8 cancer diagnostic

 

 

August 11, 2020

​

Adecto Pharmaceuticals president Dr. Gail Sonenshein receives Tufts University School of Medicine 2020 Zucker Award for outstanding career achievements in women's health research

 

 

May 24, 2019

​

Adecto Pharmaceuticals awarded Phase I NCI SBIR grant for development of ADAM8 cancer diagnostic

 

 

October 22, 2018

​

Adecto Pharmaceuticals awarded multimillion-dollar NCI SBIR grant to continue development of ADAM8 targeted therapy

 

 

March 1, 2018

​

Adecto Pharmaceuticals selected to participate in MassBio’s MassCONNECT mentoring program

 

 

April 2, 2017

​

Adecto Pharmaceuticals presents poster on selection of lead candidate therapeutic antibodies at the 2017 AACR annual meeting

 

 

April 15, 2016

​

Adecto Pharmaceuticals awarded Phase I NCI STTR grant for the development of ADAM8 targeted therapies

 

 

April 13, 2015

​

Adecto Pharmaceuticals wins Tufts $100K New Ventures Competition

 

 

March 18, 2014

​

New Hope for Tough-to-Treat Breast Cancers

Tufts researchers find promising target in battle against aggressive tumors

 

 

bottom of page